29 recruiting, 13 completed, 12 not yet recruiting, 5 withdrawn. 38 Phase 1, 12 Phase 2, 11 Not applicable, 2 Early Phase 1, 1 Phase 3.
Follow Solid Tumor Cancer: new trials by email Literature Review of Solid Tumor Cancer trials Research Report on Solid Tumor Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multidisciplinary Decision-Making in Oncology CMAT-Supported Multidisciplinary Assessment Pathway, Standard Multidisciplinary Assessment - Solid Tumor Cancer | Not applicable | Not yet recruiting | Muğla Sıtkı Koçman University | 60 | 2027-01-10 | 2026-10-06 |
| Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients 68Ga-FAPI-46 - Solid Tumor Cancer, Solid Tumor Malignancy | Early Phase 1 | Withdrawn | Eben Rosenthal | 2027-01-01 | 2026-01-21 | |
| Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid Tumors umbilical cord blood - Pediatric Cancer, Solid Tumor Cancer | Not applicable | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 10 | 2026-10-01 | 2026-10-08 |
| ITR-251 in Patients With Advanced Solid Tumors ITR-251, ITR-251 at RP2D, ARPI therapy - Solid Tumor Cancer, Castration Resistant Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | ITERIA BIOPHARMA, S.L. | 46 | 2026-10-01 | 2026-10-13 |
| Cancer Nutrition Study - A Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors High-Fermented Food Diet, HI-MAIZE 260 Resistant Starch - Solid Tumor Cancer, Immune-Related Adverse Events | Not applicable | Not yet recruiting | Thomas Jefferson University | 50 | 2026-10-01 | 2026-10-06 |
| Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine, Fosrolapitant and Palonosetron; Dexamethasone - Solid Tumor Cancer | Phase 2 | Active not recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2026-09-14 | 2026-09-25 |
| Oncogeriatric Screening and Evaluation Program Solid Tumor Cancer | Not yet recruiting | Latin American Cooperative Oncology Group | 412 | 2026-09-01 | 2026-09-04 | |
| Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing Standard of Care chemotherapy Following an Algorithm, Standard of Care chemotherapy following CTCAE criteria - Solid Tumor Cancer | Phase 1 / Phase 2 | Not yet recruiting | Barbara Ann Karmanos Cancer Institute | 886 | 2026-09-01 | 2026-08-28 |
| Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer Cancer, Solid Tumor Cancer | Recruiting | Tempus AI | 1000 | 2026-08-01 | 2026-08-10 | |
| Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial Time-restricted eating, Questionnaire Administration, Biospecimen Collection - Rectal Cancer Stage II, Rectal Cancer Stage III | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 100 | 2026-07-23 | 2026-07-29 |
| Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors CP-IL22BP mRNA intratumorally injection - mRNA Vaccine, Solid Tumor Cancer | Phase 1 | Recruiting | West China Hospital | 18 | 2026-07-13 | 2026-07-14 |
| AI-Driven Tumor Response Evaluation for Solid Tumors Observational Data Collection - Solid Tumor Cancer, Neoplasms | Not yet recruiting | Shanghai Zhongshan Hospital | 6120 | 2026-07-01 | 2026-07-08 | |
| JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg - Malignancies, Solid Malignant Tumor | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 14 | 2026-06-25 | 2026-08-11 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors Gemcitabine, Mitomycin C, Thalidomide - Solid Tumor Cancer | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 60 | 2026-06-01 | 2026-06-26 |
| Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors NCP-CD47 siRNA intratumorally injection - Solid Tumor Cancer, Metastases | Phase 1 | Not yet recruiting | West China Hospital | 9 | 2026-05-30 | 2026-05-13 |
| QLS5212 for Participants With Advanced Solid Tumors QLS5212 - Solid Tumor Cancer | Phase 1 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 100 | 2026-05-11 | 2026-05-19 |
| METEL Study Which is to Collect Urine Samples From Patients to Analyse Their Chemistry to Assess How Close to Death the Patient is at Point of Sample When They Have a Solid Cancer Tumour Diagnosis Solid Tumor Cancer | Recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | 1327 | 2026-05-01 | 2026-09-30 | |
| Imaging of Solid Tumors Using DLL3 SPECT 111In-ABD147, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) - Solid Tumor Cancer, Castration Resistant Prostate Cancer | Early Phase 1 | Withdrawn | Thomas Hope | 2026-04-30 | 2026-04-29 | |
| Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors SYS6043 - Cancer, Solid Tumor Cancer | Phase 1 | Recruiting | Conjupro Biotherapeutics, Inc. | 386 | 2026-03-03 | 2026-04-07 |
Showing 20 of 67. Sign in to see all of them.
Neoplasms (19) · Neoplasm Metastasis (6) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Renal Cell (5) · Head and Neck Neoplasms (5) · Small Cell Lung Carcinoma (5) · Breast Neoplasms (4) · Carcinoma, Hepatocellular (4) · Lung Neoplasms (4) · Melanoma (4) · Ovarian Neoplasms (4) · Endometrial Neoplasms (3) · Urinary Bladder Neoplasms (3) · Colorectal Neoplasms (2) · Gastrointestinal Neoplasms (2)
Neoplasms by Site (20) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Urogenital Diseases (11) · Digestive System Diseases (10) · Lung Diseases (10) · Neoplasms, Glandular and Epithelial (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Urogenital Neoplasms (10) · Digestive System Neoplasms (9) · Male Urogenital Diseases (9)
Dexamethasone (2) · Interleukin-18 (2) · ispinesib (2) · Androgen Antagonists (1) · Biopsy, Large-Core Needle (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Exercise (1) · Exercise Therapy (1) · FAPI-46 (1) · Gemcitabine (1) · Imatinib Mesylate (1) · Immunoconjugates (1)
GlaxoSmithKline (7) · West China Hospital (5) · Avenzo Therapeutics, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · A2 Biotherapeutics Inc. (1) · Ankyra Therapeutics, Inc (1) · Avelos Therapeutics Inc. (1) · Barbara Ann Karmanos Cancer Institute (1) · China Medical University Hospital (1) · Conjupro Biotherapeutics, Inc. (1) · Dragonfly Therapeutics (1) · Eben Rosenthal (1) · Elephas (1) · Exelixis (1) · Fred Hutchinson Cancer Center (1)
United States (26) · China (20) · Canada (2) · France (2) · Germany (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Italy (1) · Singapore (1) · Switzerland (1) · Turkey (Türkiye) (1)
Ann Silk, MD (1) · Anthony El-Khoueiry, MD (1) · Carissa A Low (1) · Devika Jutagir, PhD (1) · Dongmei Ji, M.D (1) · Eben Rosenthal, MD (1) · Ebrahim S. Delpassand, M.D. Chairman & Medical Director, Nuclear Medicine (1) · Eric Ng, MD (1) · Fred Hausheer, MD, FACP (1) · Jane Figueiredo, PhD, M.Sc. (1) · JinMing Yu, Phd (1) · Joanna Arch, PhD (1) · Joe Elassal, MD, MBA (1)
PMID 40791544, PMID 41310346, PMID 41484629
P50CA285275 (1), R37CA242545 (1)